Similar articles

• Further experience with rezoxane (ICRF 159; -- NSC --129943) in treating Kaposi's sarcoma.

  Olweny CL, Sikyewunda W, Otim D. Olweny CL, et al. Oncology. 1980;37(3):174-6. doi: 10.1159/000225429. Oncology. 1980. PMID: 7360489
• Phase II trial of ICRF-187 in patients with acquired immune deficiency related Kaposi's sarcoma (AIDS-KS).

  Chachoua A, Green M, Wernz J, Muggia F. Chachoua A, et al. Invest New Drugs. 1989 Nov;7(4):327-31. doi: 10.1007/BF00173762. Invest New Drugs. 1989. PMID: 2513285
• [A new Soviet cytostatic drug--prospidine--used in treatment of Kaposi's angioreticulosis].

  Smelov NS, Kalamkarian AA. Smelov NS, et al. Vestn Dermatol Venerol. 1970 Sep;44(9):31-5. Vestn Dermatol Venerol. 1970. PMID: 5523954 Russian. No abstract available.
• Management of Kaposi's sarcoma. Chemotherapy I.

  Vogel CL. Vogel CL. Antibiot Chemother (1971). 1981;29:82-7. Antibiot Chemother (1971). 1981. PMID: 7027912 Review. No abstract available.
• Kaposi's sarcoma in rheumatic diseases.

  Louthrenoo W, Kasitanon N, Mahanuphab P, Bhoopat L, Thongprasert S. Louthrenoo W, et al. Semin Arthritis Rheum. 2003 Apr;32(5):326-33. doi: 10.1053/sarh.2002.50000. Semin Arthritis Rheum. 2003. PMID: 12701043 Review.